<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="114232">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01798667</url>
  </required_header>
  <id_info>
    <org_study_id>DA8031_PE_II</org_study_id>
    <nct_id>NCT01798667</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Evaluate the Efficacy and Safety of DA-8031 in Male Patients With Premature Ejaculation</brief_title>
  <official_title>A Randomized, Double-blind, Double-dummy, Placebo-controlled, Therapeutic Exploratory Clinical Trial to Evaluate the Efficacy and Safety of DA-8031 After Oral Administration in Male Patients With Premature Ejaculation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dong-A Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dong-A Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <authority>South Korea: Korea Food and Drug Administration (KFDA)</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the efficacy and safety of DA-8031 and to decide the
      optimal dose of DA-8031 in male patients with premature ejaculation after oral
      administration on-demand.

      The investigators hypothesized that newly-developed DA-8031 would effect in delaying
      ejaculation in patients with premature ejaculation (PE).

      Design:

      Placebo-controlled, Randomized, Double-blind, Double-dummy, Parallel group, Fixed dose
      design
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">September 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>average IELT change</measure>
    <time_frame>From 0 week(baseline) to 8 week(end of treatment)</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>PEP, PGI</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>PEP(Primary ejaculation profile), PGI(Patient-reported global impression)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Premature Ejaculation</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>PO administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DA-8031 dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PO administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DA-8031 dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PO administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DA-8031 dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PO administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DA-8031</intervention_name>
    <arm_group_label>DA-8031 dose 1</arm_group_label>
    <arm_group_label>DA-8031 dose 2</arm_group_label>
    <arm_group_label>DA-8031 dose 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo of DA-8031, undistinguishable</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male patients aged with premature ejaculation for more than 6 months.

          -  PEDT score ≥ 11

        Exclusion Criteria:

          -  IIEF-EF domain ≤ 21

          -  Serum Creatinine ≥ 2.5 mg/dl

          -  AST, ALT &gt; 3*Upper limit of normal

          -  Subjects with hypotension(SBP/DBP&lt;90/50mmHg) or uncontrolled
             hypertension(SBP/DBP&gt;180/100mmHg)

          -  Subjects with chronic depression, psychiatric or schizophrenia,

          -  Subjects with alcohol, drug or substance abuse
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sae Woong Kim</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul St. Mary's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Du Geon Moon</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korea University Guro Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nam-Cheol Park</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pusan National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jae-Seung Paick</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tai-Young Ahn</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sung Won Lee</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ki Hak Moon</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yeongnam University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kwangsung Park</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chonnam National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jong Kwan Park</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chonbuk National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dae Yul Yang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kangdong Sacred Heart Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sung Won Lee</last_name>
    <email>drswlee@skku.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sung Won Lee</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 14, 2013</lastchanged_date>
  <firstreceived_date>January 27, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sexual Dysfunctions, Psychological</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
